

Gavin Giovannoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2392053/publications.pdf>

Version: 2024-02-01

398
papers

27,325
citations

11639

70
h-index

6990

154
g-index

413
all docs

413
docs citations

413
times ranked

18451
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. <i>Multiple Sclerosis Journal</i> , 2022, 28, 111-120.	1.4	15
2	<scp>COVID</scp>â€™19 Vaccine Response in People with Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 89-100.	2.8	119
3	Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1219-1228.	1.4	13
4	Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103409.	0.9	1
5	Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. <i>Neurodegenerative Disease Management</i> , 2022, 12, 1-7.	1.2	2
6	Update on NHS Reset and Reform achievements in 2021. <i>British Journal of Neuroscience Nursing</i> , 2022, 18, S20-S24.	0.1	1
7	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103448.	0.9	19
8	Smouldering multiple sclerosis: the â€™real MSâ€™™. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642110667.	1.5	72
9	Is EBV the cause of multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103636.	0.9	11
10	Remyelination trial failures: Repercussions of ignoring neurorehabilitation and exercise in repair. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103539.	0.9	4
11	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. <i>Lancet Regional Health - Europe, The</i> , 2022, 15, 100321.	3.0	13
12	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. <i>Clinical and Experimental Immunology</i> , 2022, 207, 263-271.	1.1	14
13	Prevalence of disability improvement in relapsingâ€™remitting multiple sclerosis patients treated with cladribine tablets. <i>European Journal of Neurology</i> , 2022, 29, 2144-2147.	1.7	2
14	Implications of Low-Titer MOG Antibodies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103746.	0.9	10
15	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. <i>JAMA Neurology</i> , 2022, 79, 359.	4.5	25
16	Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1526-1540.	1.4	16
17	Exercise training in multiple sclerosis. <i>Lancet Neurology, The</i> , 2022, 21, 313.	4.9	6
18	Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5â€™%years. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1591-1605.	1.4	19

#	ARTICLE	IF	CITATIONS
19	The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103757.	0.9	10
20	Extended dosing of monoclonal antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2001-2009.	1.4	16
21	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2022, 28, 842-846.	1.4	13
22	How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies?. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103803.	0.9	1
23	Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review. <i>Neurology and Therapy</i> , 2022, 11, 571-595.	1.4	22
24	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. <i>Lancet Neurology</i> , The, 2022, 21, 608-619.	4.9	44
25	High efficacy treatment is not enough in MS: Socioeconomic factors are key to improving outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103816.	0.9	0
26	Onset of multiple sclerosis is preventable – time to act now!. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 62, 103875.	0.9	1
27	Age-specific effects of childhood body mass index on multiple sclerosis risk. <i>Journal of Neurology</i> , 2022, 269, 5052-5060.	1.8	5
28	The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 2754-2760.	1.7	5
29	Personalised immunotherapy in active multiple sclerosis using injectable cladribine: Follow-up of the BartsMS cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A2.3-A2.	0.9	0
30	021... Determinants of natalizumab-associated PML outcomes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A20.1-A20.	0.9	0
31	229... Developing novel smell test for Parkinson's disease using microencapsulation of essential oils in alginate. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A79.3-A79.	0.9	0
32	026... Gene-environment interactions in multiple sclerosis: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A21.3-A22.	0.9	0
33	091... Evaluation of remote assessments for multiple sclerosis in a real-world setting. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A129.1-A129.	0.9	0
34	043... Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A27.1-A27.	0.9	0
35	Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. <i>Journal of Neurology</i> , 2022, 269, 5093-5104.	1.8	7
36	022... Updated safety of cladribine tablets in multiple sclerosis patients: integrated safety analysis and post-approval data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A20.2-A20.	0.9	0

#	ARTICLE	IF	CITATIONS
37	045â€¦ Effect of siponimod on cortical grey matter and thalamic volume in secondary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A27.3-A27.	0.9	0
38	015â€¦ Reduced risk of secondary progressive multiple sclerosis by treatment with clad-ribine tablets: CLARITY study analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A18.2-A18.	0.9	0
39	018â€¦ Disease control beyond NEDA: the value of non-clinical measures to determine treatment response to natalizumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A19.1-A19.	0.9	0
40	211â€¦ The prevalence and characteristics of multiple sclerosis-associated uveitis in UK biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A74.2-A74.	0.9	0
41	120â€¦ The impact of socioeconomic status and comorbidities on emergency admissions in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A138.3-A138.	0.9	0
42	Parkinsonâ€™s disease determinants, prediction and gene-environment interactions: a UK Biobank study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A7.3-A8.	0.9	0
43	Multiple sclerosis is one disease. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103961.	0.9	4
44	Chronic lesion activity and disability progression in secondary progressive multiple sclerosis. <i>BMJ Neurology Open</i> , 2022, 4, e000240.	0.7	12
45	EBV as the â€œgluten of MSâ€•hypothesis provides a rationale for trialing antiviral therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 104007.	0.9	0
46	Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1564-1576.	1.4	16
47	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. <i>Multiple Sclerosis Journal</i> , 2021, 27, 922-932.	1.4	5
48	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102624.	0.9	1
49	Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects. <i>Drugs</i> , 2021, 81, 207-231.	4.9	81
50	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. <i>International Journal of Epidemiology</i> , 2021, 49, 2051-2057.	0.9	9
51	Is multiple sclerosis overdiagnosed?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 47, 102721.	0.9	2
52	Amyloidoma mimicking multiple sclerosis. <i>Practical Neurology</i> , 2021, 21, 344-345.	0.5	1
53	Air pollution and multiple sclerosis risk. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102797.	0.9	3
54	Predicting disability worsening in relapsing and progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2021, 34, 312-321.	1.8	9

#	ARTICLE	IF	CITATIONS
55	B cell therapy and the use of RNA-based COVID-19 vaccines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102887.	0.9	5
56	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021, 23, e29558.	2.1	8
57	Improving estimation of Parkinson's disease risk: the enhanced PREDICT-PD algorithm. <i>Npj Parkinson's Disease</i> , 2021, 7, 33.	2.5	13
58	Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 50, 102931.	0.9	2
59	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	32
60	Gender issues during the times of COVID-19 pandemic. <i>European Journal of Neurology</i> , 2021, 28, e73-e77.	1.7	6
61	Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110242.	0.5	4
62	COVID-19 vaccines and multiple sclerosis disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103155.	0.9	12
63	Can rheumatologists stop causing demyelinating disease?. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103057.	0.9	4
64	Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement. <i>Journal of Neuroimmunology</i> , 2021, 357, 577627.	1.1	33
65	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5Åmg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies. <i>Advances in Therapy</i> , 2021, 38, 4975-4985.	1.3	14
66	Evaluation of remote assessments for multiple sclerosis in an in-home setting. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103125.	0.9	2
67	Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103284.	0.9	1
68	Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 295-302.	0.9	15
69	Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e376-e386.	1.5	64
70	Optimising classification of Parkinson's disease based on motor, olfactory, neuropsychiatric and sleep features. <i>Npj Parkinson's Disease</i> , 2021, 7, 87.	2.5	4
71	Measuring treatment response to advance precision medicine for multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2166-2173.	1.7	6
72	Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576.	1.5	5

#	ARTICLE	IF	CITATIONS
73	Antibodies to neurofilament light as potential biomarkers in multiple sclerosis. <i>BMJ Neurology Open</i> , 2021, 3, e000192.	0.7	1
74	Derisking CD20-therapies for long-term use. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 57, 103418.	0.9	2
75	It is time to move to alternative clinical trial designs: Reconsidering the holy grail of trial methodology. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103426.	0.9	0
76	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110582.	1.5	9
77	Predicting Multiple Sclerosis: Challenges and Opportunities. <i>Frontiers in Neurology</i> , 2021, 12, 761973.	1.1	7
78	Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. <i>Frontiers in Immunology</i> , 2021, 12, 763433.	2.2	2
79	Inclusion criteria used in trials of people with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 279-283.	1.4	3
80	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020, 26, 296-310.	3.5	178
81	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 335-358.	1.4	3
82	CSF neurofilament light chain testing as an aid to determine treatment strategies in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e880.	3.1	12
83	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , The, 2020, 19, 988-997.	4.9	64
84	Distinguishing physiological versus pathological serum NFL levels in multiple sclerosis will require serial measurements. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102477.	0.9	0
85	Serum neurofilament-light concentration and real-world outcome in MS. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117079.	0.3	10
86	Parkinson's disease determinants, prediction and gene-environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	0.9	59
87	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102572.	0.9	36
88	Regarding: Nicotinic acetylcholine receptors $\alpha 7$ and $\alpha 9$ modify tobacco smoke risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096994.	1.4	0
89	The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102174.	0.9	62
90	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102209.	0.9	4

#	ARTICLE	IF	CITATIONS
91	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 44, 102241.	0.9	21
92	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. <i>BMC Public Health</i> , 2020, 20, 912.	1.2	90
93	Detecting and predicting neutralization of alemtuzumab responses in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	7
94	Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102259.	0.9	8
95	Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. <i>JAMA Neurology</i> , 2020, 77, 1132.	4.5	245
96	The impact of social capital on patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2020, 142, 58-65.	1.0	8
97	Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1281-1297.	1.4	55
98	The COVID-19 pandemic and the use of MS disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 102073.	0.9	153
99	Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102024.	0.9	6
100	Protecting people with multiple sclerosis through vaccination. <i>Practical Neurology</i> , 2020, 20, 435.1-445.	0.5	40
101	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093501.	1.5	23
102	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.5	28
103	Health-care disparities for people with multiple sclerosis. <i>Lancet Neurology</i> , The, 2020, 19, 207-208.	4.9	7
104	A cell-based assay for the detection of neutralizing antibodies against alemtuzumab. <i>BioTechniques</i> , 2020, 68, 185-190.	0.8	2
105	The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 124.	2.2	21
106	GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains. <i>Scientific Reports</i> , 2020, 10, 1860.	1.6	6
107	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2020, 19, 214-225.	4.9	81
108	BMI and low vitamin D are causal factors for multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	67

#	ARTICLE	IF	CITATIONS
109	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. <i>Annals of Neurology</i> , 2020, 87, 599-608.	2.8	21
110	World Health Organization Essential Medicines List: Multiple sclerosis disease-modifying therapies application. <i>Multiple Sclerosis Journal</i> , 2020, 26, 153-158.	1.4	5
111	Ageing and multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101953.	0.9	1
112	Severe skin reactions associated with cladribine in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102140.	0.9	6
113	Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 483-492.	0.9	26
114	Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 41, 102135.	0.9	42
115	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020, 267, 2851-2864.	1.8	8
116	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. <i>Neurology and Therapy</i> , 2020, 9, 359-374.	1.4	24
117	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020, 43, 635-643.	1.4	20
118	Enzymatic degradation of <i>scprNA</i> causes widespread protein aggregation in cell and tissue lysates. <i>EMBO Reports</i> , 2020, 21, e49585.	2.0	26
119	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.9	11
120	CLINICAL VIEWPOINT: Immunosuppression and COVID-19. <i>Advances in Clinical Neuroscience & Rehabilitation: ACNR</i> , 2020, 19, 8-9.	0.1	0
121	Dare we mention the C-word?. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 43, 102340.	0.9	0
122	Remote testing of vitamin D levels across the UK MS population—a case control study. <i>PLoS ONE</i> , 2020, 15, e0241459.	1.1	2
123	Remote testing of vitamin D levels across the UK MS population—a case control study. , 2020, 15, e0241459.		0
124	Remote testing of vitamin D levels across the UK MS population—a case control study. , 2020, 15, e0241459.		0
125	Remote testing of vitamin D levels across the UK MS population—a case control study. , 2020, 15, e0241459.		0
126	Remote testing of vitamin D levels across the UK MS population—a case control study. , 2020, 15, e0241459.		0

#	ARTICLE	IF	CITATIONS
127	Do we have equipoise when it comes to how we treat active multiple sclerosis?. <i>Lancet Neurology, The</i> , 2019, 18, 909-911.	4.9	3
128	Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641985498.	1.5	76
129	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2019, 18, 845-856.	4.9	110
130	Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care. <i>Advances in Therapy</i> , 2019, 36, 3238-3252.	1.3	20
131	Cerebrospinal fluid NCAM levels are modulated by disease-modifying therapies. <i>Acta Neurologica Scandinavica</i> , 2019, 139, 422-427.	1.0	6
132	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 168-174.	0.9	94
133	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 19-25.	0.9	13
134	Screening performance of abbreviated versions of the UPSIT smell test. <i>Journal of Neurology</i> , 2019, 266, 1897-1906.	1.8	37
135	Survival: the ultimate long-term outcome in multiple sclerosis. <i>Brain</i> , 2019, 142, 1166-1167.	3.7	2
136	Chronic-relapsing varicella zoster meningitis – Successfully treated with varicella vaccine. <i>Journal of Infection</i> , 2019, 79, 61-74.	1.7	0
137	Visibility and representation of women in multiple sclerosis research. <i>Neurology</i> , 2019, 92, 713-719.	1.5	13
138	Social capital: Implications for neurology. <i>Brain and Behavior</i> , 2019, 9, e01169.	1.0	7
139	Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 247-253.	0.9	10
140	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 29, 157-167.	0.9	94
141	UK consensus on pregnancy in multiple sclerosis: – Association of British Neurologists™ guidelines. <i>Practical Neurology</i> , 2019, 19, 106-114.	0.5	118
142	Is the –MS establishment™ biased; the case for addressing gender inequality in the field of MS?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 153-154.	0.9	3
143	Should our treatment target in MS include the intrathecal plasma cell response?. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, A1-A2.	0.9	1
144	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019, 25, 627-636.	1.4	90

#	ARTICLE	IF	CITATIONS
145	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	1.4	55
146	The unintended consequences of NICE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 247-248.	0.9	0
147	Learning ability correlates with brain atrophy and disability progression in RRMS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 38-43.	0.9	18
148	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 819-827.	1.4	46
149	The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 285-290.	1.8	13
150	No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. <i>Journal of Neurology</i> , 2018, 265, 1089-1095.	1.8	67
151	Complexity of MS management in the current treatment era. <i>Neurology</i> , 2018, 90, 761-762.	1.5	4
152	Are the high-costs of MS disease-modifying therapies justified?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, A3-A5.	0.9	2
153	Disease-modifying treatments for early and advanced multiple sclerosis: a new treatment paradigm. <i>Current Opinion in Neurology</i> , 2018, 31, 233-243.	1.8	116
154	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing/remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775336.	1.5	45
155	Alemtuzumab depletion failure can occur in multiple sclerosis. <i>Immunology</i> , 2018, 154, 253-260.	2.0	32
156	Editors' Welcome. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, A1-A2.	0.9	0
157	No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876064.	0.5	32
158	Human Endogenous Retroviruses in Neurological Diseases. <i>Trends in Molecular Medicine</i> , 2018, 24, 379-394.	3.5	212
159	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , 2018, 391, 1263-1273.	6.3	684
160	Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells. <i>Journal of Neurology</i> , 2018, 265, 1199-1209.	1.8	120
161	Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. <i>Multiple Sclerosis Journal</i> , 2018, 24, 222-226.	1.4	47
162	Psychiatric disorders in children with demyelinating diseases of the central nervous system. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1243-1250.	1.4	20

#	ARTICLE	IF	CITATIONS
163	A brief history of NEDA. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 228-230.	0.9	40
164	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1883-1891.	1.4	2
165	Vitamin D supplementation. <i>Practical Neurology</i> , 2018, 18, 35-42.	0.5	43
166	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1594-1604.	1.4	227
167	Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1725-1736.	1.4	3
168	Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 153-160.	0.9	101
169	WED 186-Effect of cladribine tablets on immune cells in patients with ms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A26.2-A26.	0.9	0
170	WED 184-Cladribine tablets in clarity patients with high disease activity ms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A25.3-A26.	0.9	0
171	Patient Power Revolution in Multiple Sclerosis: Navigating the New Frontier. <i>Neurology and Therapy</i> , 2018, 7, 179-187.	1.4	23
172	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1862-1870.	1.4	41
173	e-Health and multiple sclerosis: An update. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1657-1664.	1.4	63
174	Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2018, 379, 1017-1027.	13.9	237
175	Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis. <i>Brain</i> , 2018, 141, 2834-2847.	3.7	43
176	O39-Rates of lymphopenia in years 1-4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A16.2-A16.	0.9	3
177	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018, 84, 527-536.	2.8	42
178	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	0.8	43
179	O67-Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A27.2-A28.	0.9	0
180	Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study. <i>Journal of Neurology</i> , 2018, 265, 1795-1802.	1.8	7

#	ARTICLE	IF	CITATIONS
181	Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 20-27.	0.9	16
182	A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 24, 123-128.	0.9	25
183	Women on multiple sclerosis clinical trial steering committees. <i>Annals of Neurology</i> , 2018, 84, 329-330.	2.8	10
184	Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 197-199.	0.9	14
185	Is cognitive impairment in multiple sclerosis reversible?. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, A1.	0.9	0
186	Peripheral blood neurofilament light chain levels: the neurologist's C-reactive protein?. <i>Brain</i> , 2018, 141, 2235-2237.	3.7	26
187	Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731878376.	0.5	7
188	Cladribine: mechanisms and mysteries in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 1266-1271.	0.9	61
189	No Evident Disease Activity"More Than a Risky Ambition?. <i>JAMA Neurology</i> , 2018, 75, 781.	4.5	9
190	Increased expression of colony-stimulating factor-1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss. <i>Glia</i> , 2018, 66, 2108-2125.	2.5	36
191	Cerebrospinal Fluid Biomarkers in Human Spinal Cord Injury from a Phase II Minocycline Trial. <i>Journal of Neurotrauma</i> , 2018, 35, 1918-1928.	1.7	24
192	WED 185...Clarity: mri outcomes in high disease activity relapsing ms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A26.1-A26.	0.9	0
193	THUR 192...Yearly lymphopenia rates in cladribine tablets-treated rms patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A27.3-A28.	0.9	0
194	Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 70-78.	0.9	92
195	Should we rebrand multiple sclerosis a dementia?. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, 79-81.	0.9	10
196	Serum neurofilament is associated with progression of brain atrophy and disability in early MS. <i>Neurology</i> , 2017, 88, 826-831.	1.5	168
197	PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 219-226.	2.2	59
198	Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. <i>EBioMedicine</i> , 2017, 16, 41-50.	2.7	225

#	ARTICLE	IF	CITATIONS
199	Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 14, 46-50.	0.9	18
200	How to start a blog. <i>Practical Neurology</i> , 2017, 17, 224-228.	0.5	1
201	The neurodegenerative prodrome in multiple sclerosis. <i>Lancet Neurology</i> , The, 2017, 16, 413-414.	4.9	29
202	Subtle motor disturbances in PREDICT-PD participants. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 212-217.	0.9	19
203	Can we afford not to prevent MS-related disability?. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1048-1049.	1.4	6
204	The "Field Hypothesis": rebound activity after stopping disease-modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 15, A1-A2.	0.9	13
205	Science is 1% inspiration and 99% biomarkers. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1442-1452.	1.4	18
206	Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. <i>JAMA Neurology</i> , 2017, 74, 961.	4.5	204
207	Editors' Welcome. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 12, A1-A2.	0.9	1
208	No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1736-1747.	1.4	18
209	"No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1179-1187.	1.4	126
210	Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis. <i>Immunology</i> , 2017, 150, 444-455.	2.0	43
211	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 221-234.	13.9	1,322
212	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017, 376, 209-220.	13.9	1,324
213	Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 18, 181-183.	0.9	33
214	Alemtuzumab CARE-MS I 5-year follow-up. <i>Neurology</i> , 2017, 89, 1107-1116.	1.5	188
215	Alemtuzumab CARE-MS II 5-year follow-up. <i>Neurology</i> , 2017, 89, 1117-1126.	1.5	232
216	Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 506-511.	1.7	16

#	ARTICLE	IF	CITATIONS
217	Tackling comorbidity in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 144-145.	0.9	7
218	Big conductance calcium-activated potassium channel openers control spasticity without sedation. <i>British Journal of Pharmacology</i> , 2017, 174, 2662-2681.	2.7	22
219	Disease modification in advanced MS: Focus on upper limb function. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1956-1957.	1.4	8
220	Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. <i>Clinical Therapeutics</i> , 2017, 39, 1671-1679.	1.1	26
221	Cladribine to Treat Relapsing Forms of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 874-887.	2.1	92
222	Personalized medicine in multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2017, 7, 13-17.	1.2	25
223	Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 172-176.	0.9	6
224	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 32-40.	0.9	9
225	Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1 ^β . <i>Journal of Neuroinflammation</i> , 2017, 14, 131.	3.1	39
226	Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1367-1376.	1.4	26
227	PO109...Is there an ethnicity bias of access to multiple services in the nhs? "the barts health experience. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A40.2-A40.	0.9	0
228	PO138...High disease activity in relapsing multiple sclerosis (rms). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A49.1-A49.	0.9	0
229	PO137...Efficacy of cladribine tablets in high disease activity rms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A48.3-A49.	0.9	0
230	PO151...Infections in patients with multiple sclerosis on alemtuzumab "should antibiotic prophylaxis be standard?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A52.3-A53.	0.9	0
231	PO136...Durable efficacy of cladribine tablets: clarity+extension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, A48.2-A48.	0.9	0
232	Epstein-Barr "negative MS: a true phenomenon?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e318.	3.1	33
233	A multicentre randomised controlled TRial of IntraVENous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). <i>Health Technology Assessment</i> , 2017, 21, 1-50.	1.3	20
234	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309690.	0.9	90

#	ARTICLE	IF	CITATIONS
235	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	1.1	11
236	Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S5-S48.	0.9	280
237	Why do you have to be lucky to get the MS treatment you deserve?. Multiple Sclerosis and Related Disorders, 2016, 8, A3-A4.	0.9	2
238	Time and brain health both matter in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 9, S1-S3.	0.9	4
239	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. Neurology, 2016, 87, 1985-1992.	1.5	55
240	Editorsâ€™ Welcome. Multiple Sclerosis and Related Disorders, 2016, 7, A1-A2.	0.9	0
241	Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Practical Neurology, 2016, 16, 389-393.	0.5	39
242	The importance of a multi-disciplinary perspective and patient activation programmes in MS management. Multiple Sclerosis Journal, 2016, 22, 34-46.	1.4	44
243	Pediatric multiple sclerosis. Neurology, 2016, 87, S103-9.	1.5	44
244	A practical review of the neuropathology and neuroimaging of multiple sclerosis. Practical Neurology, 2016, 16, 279-287.	0.5	30
245	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β -1a in MS. Neurology, 2016, 87, 1464-1472.	1.5	28
246	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurology, 2016, 16, 117.	0.8	40
247	How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 10, 127-133.	0.9	6
248	ALEMTUZUMAB IMPROVES EDSS FUNCTIONAL SYSTEMS SCORES IN RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.38-e1.	0.9	0
249	Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategyâ€“YES. Multiple Sclerosis Journal, 2016, 22, 1397-1400.	1.4	16
250	Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies. Multiple Sclerosis and Related Disorders, 2016, 9, 36-46.	0.9	48
251	Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954.	4.5	17
252	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 259-269.	4.9	168

#	ARTICLE	IF	CITATIONS
253	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 6, 49-53.	0.9	47
254	IgG4-related disease: a rare but treatable cause of refractory intracranial hypertension. <i>Practical Neurology</i> , 2016, 16, 235-239.	0.5	9
255	How long is the presymptomatic phase of multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 12-13.	0.9	9
256	Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e202.	3.1	34
257	Gender identity disorders and multiple sclerosis risk: A national record-linkage study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1759-1762.	1.4	24
258	Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. <i>Neurology and Therapy</i> , 2016, 5, 45-57.	1.4	33
259	Optimizing treatment success in multiple sclerosis. <i>Journal of Neurology</i> , 2016, 263, 1053-1065.	1.8	155
260	ALEMTUZUMAB IMPROVES 3-YEAR QUALITY OF LIFE IN CARE-MS II. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.9-e4.	0.9	0
261	Web-based assessment of Parkinson's prodromal markers identifies GBA variants. <i>Movement Disorders</i> , 2015, 30, 1002-1003.	2.2	6
262	Systematic review and meta-analysis of salivary protein concentration in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1971-1972.	2.2	2
263	Timing is everything in the treatment of multiple sclerosis. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014208960-bcr2014208960.	0.2	1
264	Is it time to target no evident disease activity (NEDA) in multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 329-333.	0.9	275
265	Multiple sclerosis outpatient future groups: improving the quality of participant interaction and ideation tools within service improvement activities. <i>BMC Health Services Research</i> , 2015, 15, 105.	0.9	27
266	Switching from natalizumab to fingolimod. <i>Neurology</i> , 2015, 85, 29-39.	1.5	110
267	Evaluating more naturalistic outcome measures. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015, 2, e162.	3.1	57
268	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 83-84.	0.9	7
269	Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. <i>Biosensors and Bioelectronics</i> , 2015, 68, 660-667.	5.3	69
270	Do neutralising antibodies against exogenous interferon-beta inhibit endogenous signalling pathways?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 88-91.	0.9	4

#	ARTICLE	IF	CITATIONS
271	HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 9-12.	0.9	77
272	The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 3-5.	0.9	11
273	Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 202-218.	0.9	85
274	Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 565-573.	0.9	91
275	Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids. <i>Journal of Neuroimmune Pharmacology</i> , 2015, 10, 281-292.	2.1	42
276	Editors' Welcome. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, A1-A3.	0.9	0
277	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. <i>Practical Neurology</i> , 2015, 15, 273-279.	0.5	169
278	Neurofilament light chain. <i>Neurology</i> , 2015, 84, 2247-2257.	1.5	412
279	Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. <i>Neurology</i> , 2015, 84, 1639-1643.	1.5	153
280	The role of infections in Behçet disease and neuro-Behçet syndrome. <i>Autoimmunity Reviews</i> , 2015, 14, 609-615.	2.5	18
281	ELEVATED SALIVARY DJ-1 IN PARKINSON'S DISEASE IS ASSOCIATED WITH ALTERED SALIVARY SECRETION. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, e4.111-e4.	0.9	0
282	Elevated salivary protein in Parkinson's disease and salivary DJ-1 as a potential marker of disease severity. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1251-1255.	1.1	41
283	Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. <i>Clinical Therapeutics</i> , 2015, 37, 2543-2551.	1.1	9
284	Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS). <i>Multiple Sclerosis Journal</i> , 2015, 21, 57-66.	1.4	56
285	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 273-279.	0.9	144
286	Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate. <i>International Journal of MS Care</i> , 2015, 17, 236-243.	0.4	47
287	Bradykinesia-Akinesia Incoordination Test: Validating an Online Keyboard Test of Upper Limb Function. <i>PLoS ONE</i> , 2014, 9, e96260.	1.1	52
288	The Refinement of Genetic Predictors of Multiple Sclerosis. <i>PLoS ONE</i> , 2014, 9, e96578.	1.1	15

#	ARTICLE	IF	CITATIONS
289	Mononeuritis multiplex as the first presentation of refractory sarcoidosis responsive to etanercept. <i>BMC Neurology</i> , 2014, 14, 237.	0.8	11
290	Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. <i>Multiple Sclerosis Journal</i> , 2014, 20, 464-470.	1.4	25
291	Assessing treatment response to interferon- β . <i>Neurology</i> , 2014, 82, 248-254.	1.5	61
292	PREDICT-PD: Identifying risk of Parkinson's disease in the community: methods and baseline results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 31-37.	0.9	90
293	IMMUNOCOMPETENT PML-AN IMMUNOLOGICAL SCOTOMA?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.16-e4.	0.9	0
294	Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 705-711.	0.9	30
295	No Evidence of Disease Activity: Indirect Comparisons of Oral Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. <i>Advances in Therapy</i> , 2014, 31, 1134-1154.	1.3	83
296	Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 274-278.	0.9	51
297	Developing Biomarkers for MS. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 26, 179-194.	0.8	5
298	SURVEY OF UK MEDICAL STUDENTS ON THE PERCEPTION OF NEUROLOGY. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, e4.157-e4.	0.9	0
299	Alcohol Misuse Disorders and Multiple Sclerosis Risk. <i>JAMA Neurology</i> , 2014, 71, 1188.	4.5	19
300	Multiple sclerosis therapy and Epstein-Barr virus antibody titres. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 372-374.	0.9	15
301	Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis. <i>Journal of Neurology</i> , 2014, 261, 316-323.	1.8	18
302	Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. <i>Brain</i> , 2014, 137, 92-108.	3.7	36
303	MSer - A new, neutral descriptor for someone with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 31-33.	0.9	4
304	Effects of Delayed-Release Dimethyl Fumarate (DMF) on Health-Related Quality of Life in Patients With Relapsing-Remitting Multiple Sclerosis: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies. <i>Clinical Therapeutics</i> , 2014, 36, 1958-1971.	1.1	36
305	Natalizumab to fingolimod washout in patients at risk of PML. <i>Neurology</i> , 2014, 82, 1196-1197.	1.5	16
306	Multiple sclerosis in the Iranian immigrant population of BC, Canada: prevalence and risk factors. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1182-1188.	1.4	24

#	ARTICLE	IF	CITATIONS
307	Simvastatin in patients with progressive multiple sclerosis. <i>Lancet, The</i> , 2014, 384, 952.	6.3	2
308	Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1355-1362.	1.4	32
309	Cerebrospinal fluid analysis. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2014, 122, 681-702.	1.0	31
310	Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB ₁ cannabinoid receptor agonists. <i>FASEB Journal</i> , 2014, 28, 117-130.	0.2	32
311	CCSVI-A. A call to clinicians and scientists to vocalise in an Internet age. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 143-146.	0.9	11
312	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology, The</i> , 2014, 13, 472-481.	4.9	83
313	Epstein-Barr virus, latitude and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 362-365.	1.4	30
314	Serum levels of 25-hydroxy vitamin D in normal Biozzi and C57BL/6 mice and during the course of chronic relapsing experimental autoimmune encephalomyelitis (CR EAE). <i>Inflammation Research</i> , 2013, 62, 659-667.	1.6	8
315	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2505-2510.	1.8	35
316	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013, 260, 1136-1146.	1.8	46
317	Editorial. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 153.	0.9	0
318	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. <i>Practical Neurology</i> , 2013, 13, 70-79.	0.5	24
319	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 162-166.	1.4	139
320	Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis. <i>Acta Neuropathologica Communications</i> , 2013, 1, 84.	2.4	26
321	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013, 381, 2167-2175.	6.3	269
322	Editors' welcome and a working definition for a multiple sclerosis cure. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 65-67.	0.9	59
323	ECTRIMS 2012: Treatment highlights. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 68-72.	0.9	1
324	Epstein-Barr virus and multiple sclerosis: association or causation?. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 287-297.	1.4	45

#	ARTICLE	IF	CITATIONS
325	Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study. <i>Journal of Neurology</i> , 2013, 260, 2297-2305.	1.8	62
326	Neural cell adhesion molecules in brain plasticity and disease. <i>Multiple Sclerosis and Related Disorders</i> , 2013, 2, 13-20.	0.9	33
327	THINK OUTSIDE THE BOX, COLLAPSE THE BOX, AND TAKE A SHARP KNIFE TO IT!. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.83-e2.	0.9	0
328	TOWARDS AN ENDOPHENOTYPE IN MULTIPLE SCLEROSIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, e2.147-e2.	0.9	3
329	Biomarker Report from the Phase II Lamotrigine Trial in Secondary Progressive MS – Neurofilament as a Surrogate of Disease Progression. <i>PLoS ONE</i> , 2013, 8, e70019.	1.1	48
330	Genetic Background Can Result in a Marked or Minimal Effect of Gene Knockout (GPR55 and CB2) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i> <i>2013, 8, e76907.</i>	1.1	43
331	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. <i>PLoS ONE</i> , 2013, 8, e75091.	1.1	375
332	Neuroprotection in a Novel Mouse Model of Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e79188.	1.1	32
333	Individualizing treatment goals and interventions for people with MS. <i>Current Opinion in Neurology</i> , 2012, 25, S20-S27.	1.8	15
334	Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 298-304.	0.9	171
335	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2012, 380, 1819-1828.	6.3	1,041
336	Meta-analysis of early nonmotor features and risk factors for Parkinson disease. <i>Annals of Neurology</i> , 2012, 72, 893-901.	2.8	607
337	Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2012, 32, 15-27.	1.1	11
338	Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2012, 367, 1098-1107.	13.9	1,493
339	The REFLEX study: a missed opportunity?. <i>Lancet Neurology, The</i> , 2012, 11, 22-24.	4.9	3
340	The diagnostic criteria for multiple sclerosis: From Charcot to McDonald. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 9-14.	0.9	37
341	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 49-54.	0.9	29
342	Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 29-38.	0.9	60

#	ARTICLE	IF	CITATIONS
343	The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 64-75.	0.9	28
344	Emerging disease modifying treatmentsâ€™A therapeutics update fromECTRIMS/ACTRIMS, Amsterdam, 2011. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 56-58.	0.9	0
345	Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 610-623.	0.8	29
346	Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course. <i>International Journal of MS Care</i> , 2012, 14, 105-114.	0.4	19
347	Promising Emerging Therapies for Multiple Sclerosis. <i>Neurologic Clinics</i> , 2011, 29, 435-448.	0.8	8
348	Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 939-948.	1.4	52
349	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e16149.	1.1	220
350	More to come: Humoral immune responses in MS. <i>Journal of Neuroimmunology</i> , 2011, 240-241, 13-21.	1.1	7
351	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. <i>Lancet Neurology</i> , The, 2011, 10, 329-337.	4.9	199
352	Fingolimod modulates microglial activation to augment markers of remyelination. <i>Journal of Neuroinflammation</i> , 2011, 8, 76.	3.1	127
353	After the storm. <i>Neurology</i> , 2011, 76, 1200-1201.	1.5	18
354	Therapies for multiple sclerosis: considerations in the pediatric patient. <i>Nature Reviews Neurology</i> , 2011, 7, 109-122.	4.9	43
355	Recent developments in oral medications for the treatment of multiple sclerosis. <i>Future Neurology</i> , 2010, 5, 167-172.	0.9	0
356	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. <i>Lancet Neurology</i> , The, 2010, 9, 727-739.	4.9	459
357	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	0.6	86
358	Neural cell adhesion molecule â€™ Description of a CSF ELISA method and evidence of reduced levels in selected neurological disorders. <i>Journal of Neuroimmunology</i> , 2010, 225, 118-122.	1.1	30
359	Multiple sclerosis: a practical overview for clinicians. <i>British Medical Bulletin</i> , 2010, 95, 79-104.	2.7	80
360	Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the â€™Spinal Tapâ€™. <i>Multiple Sclerosis Journal</i> , 2010, 16, 285-286.	1.4	19

#	ARTICLE	IF	CITATIONS
361	The McDonald Criteria for Multiple Sclerosis: time for clarification. <i>Multiple Sclerosis Journal</i> , 2010, 16, 566-575.	1.4	43
362	A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 416-426.	13.9	791
363	Current and Future Role of Interferon Beta in the Therapy of Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 715-726.	0.5	15
364	An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious Mononucleosis. <i>PLoS ONE</i> , 2010, 5, e12496.	1.1	260
365	Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. <i>Lancet Neurology</i> , The, 2009, 8, 254-260.	4.9	430
366	The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. <i>Journal of Neurology</i> , 2009, 256, 405-415.	1.8	193
367	Antineuronal antibodies in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 958-963.	2.2	17
368	Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008, 193, 120-129.	1.1	91
369	Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN γ in multiple sclerosis patients. <i>Journal of Immunological Methods</i> , 2008, 336, 113-118.	0.6	57
370	The implications of immunogenicity for protein-based multiple sclerosis therapies. <i>Journal of the Neurological Sciences</i> , 2008, 275, 7-17.	0.3	54
371	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. <i>Biomarkers in Medicine</i> , 2007, 1, 111-119.	0.6	8
372	Multiple sclerosis: the environment and causation. <i>Current Opinion in Neurology</i> , 2007, 20, 261-268.	1.8	143
373	Immunogenicity and tolerability of an investigational formulation of interferon- γ 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. <i>Clinical Therapeutics</i> , 2007, 29, 1128-1145.	1.1	38
374	The Rebif $\text{\textcircled{R}}$ New Formulation Story. <i>Drugs in R and D</i> , 2007, 8, 335-348.	1.1	32
375	Antineuronal antibody status and phenotype analysis in Tourette's syndrome. <i>Movement Disorders</i> , 2007, 22, 1424-1429.	2.2	31
376	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. <i>Nature Medicine</i> , 2007, 13, 492-497.	15.2	326
377	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2006, 354, 899-910.	13.9	2,916
378	Multiple Sclerosis Cerebrospinal Fluid Biomarkers. <i>Disease Markers</i> , 2006, 22, 187-196.	0.6	51

#	ARTICLE	IF	CITATIONS
379	Infectious causes of multiple sclerosis. <i>Lancet Neurology</i> , The, 2006, 5, 887-894.	4.9	151
380	The role of antibody affinity for specific antigens in the differential diagnosis of inflammatory nervous system disorders. <i>Journal of Neuroimmunology</i> , 2006, 180, 29-32.	1.1	5
381	PANDAS: overview of the hypothesis. <i>Advances in Neurology</i> , 2006, 99, 159-65.	0.8	7
382	Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005, 165, 41-52.	1.1	70
383	Recommended Standard of Cerebrospinal Fluid Analysis in the Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 865-70.	4.9	483
384	Optimising MS disease-modifying therapies: antibodies in perspective. <i>Journal of Neurology</i> , 2004, 251, v30-v35.	1.8	3
385	Management of Secondary-Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2004, 18, 653-669.	2.7	22
386	Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. <i>Brain</i> , 2003, 126, 2191-2202.	3.7	330
387	Primary CNS Mantle Cell Lymphoma Associated with an Isolated CSF Monoclonal IgG Band. <i>European Neurology</i> , 2003, 49, 187-188.	0.6	10
388	The clinical significance of an intrathecal monoclonal immunoglobulin band. <i>Neurology</i> , 2003, 60, 1163-1166.	1.5	72
389	Strategies to treat and prevent the development of neutralizing anti-interferon- β antibodies. <i>Neurology</i> , 2003, 61, S13-7.	1.5	23
390	Multiple sclerosis and its pathophysiology. , 2002, , 1606-1619.		4
391	Poststreptococcal autoimmune dystonia with isolated bilateral striatal necrosis. <i>Developmental Medicine and Child Neurology</i> , 2002, 44, 485-489.	1.1	52
392	Human swayback disease: expanding the spectrum of diseases associated with abnormal copper metabolism. <i>Journal of Neurology</i> , 2001, 248, 707-707.	1.8	2
393	Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. <i>Annals of Neurology</i> , 2001, 50, 588-595.	2.8	189
394	Circulating antiganglioside antibodies are not associated with the development of progressive disease or cerebral atrophy in patients with multiple sclerosis. <i>Annals of Neurology</i> , 2000, 47, 684-685.	2.8	10
395	The bradykinesia akinesia incoordination test (BRAIN TEST $\frac{1}{2}$), an objective and user-friendly means to evaluate patients with Parkinsonism. <i>Movement Disorders</i> , 2000, 15, 641-647.	2.2	49
396	Increased Urinary Neopterin Excretion in Vaccinated Adults. <i>Pteridines</i> , 1996, 7, 82-86.	0.5	1

#	ARTICLE	IF	CITATIONS
397	Cladribine to treat multiple sclerosis. , 0, , 358-369.		0
398	The Potential for EBV Vaccines to Prevent Multiple Sclerosis. Frontiers in Neurology, 0, 13, .	1.1	17